Discover the most talked about and latest scientific content & concepts.

F Gehre, J Otu, L Kendall, A Forson, A Kwara, S Kudzawu, AO Kehinde, O Adebiyi, K Salako, I Baldeh, A Jallow, M Jallow, A Dagnra, K Dissé, EA Kadanga, EO Idigbe, C Onubogu, N Onyejepu, A Gaye-Diallo, A Ba-Diallo, P Rabna, M Mane, M Sanogo, B Diarra, Z Dezemon, A Sanou, M Senghore, BA Kwambana-Adams, E Demba, T Faal-Jawara, S Kumar, LD Tientcheu, A Jallow, S Ceesay, I Adetifa, A Jaye, MJ Pallen, U D'Alessandro, B Kampmann, RA Adegbola, S Mboup, T Corrah, BC de Jong and M Antonio
Drug-resistant tuberculosis (TB) is a global public health problem. Adequate management requires baseline drug-resistance prevalence data. In West Africa, due to a poor laboratory infrastructure and inadequate capacity, such data are scarce. Therefore, the true extent of drug-resistant TB was hitherto undetermined. In 2008, a new research network, the West African Network of Excellence for Tuberculosis, AIDS and Malaria (WANETAM), was founded, comprising nine study sites from eight West African countries (Burkina Faso, The Gambia, Ghana, Guinea-Bissau, Mali, Nigeria, Senegal and Togo). The goal was to establish Good Clinical Laboratory Practice (GCLP) principles and build capacity in standardised smear microscopy and mycobacterial culture across partnering laboratories to generate the first comprehensive West African drug-resistance data.
Facebook likes*
News coverage*
SC clicks
African Union member states, Atlantic slave trade, The Gambia, Burkina Faso, Economic Community of West African States, Ghana, Africa, West Africa
MeSH headings
comments powered by Disqus

* Data courtesy of